Latest on Pharmaceutical Industry


Celgene in talks to buy Juno Therapeutics: WSJ

Celgene Corp is in talks to buy Juno Therapeutics Inc (JUNO.O), which is working on an experimental gene therapy drug to treat cancer, the Wall Street Journal reported on Tuesday, citing sources familiar with the matter...Read More...

Eiger BioPharma abandons blood pressure drug after failed study

Eiger BioPharmaceuticals Inc said on Tuesday it would stop testing its drug ubenimex for the treatment of pulmonary arterial hypertension, a type of high blood pressure, after the drug failed to meet the main goal in a m..Read More...



7th Trial Master File Summit

Hyatt Regency Grand Cypress,
United States,
ExL Events


Pharmaceutical Microbiology UK

Holiday Inn Kensington Forum,
United Kingdom,
SMi Group

Press Releases

Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint

Eiger BioPharmaceuticals Inc focused on the development and commercialization of targeted therapies for rare diseases announced today Phase 2 LIBERTY study results in pulmonary arterial hypertension PAH that demonstrated.. Read More...

RXi Pharmaceuticals Announces Business Strategy to Focus on Immuno-Oncology Programs to Accelerate Growth

RXi Pharmaceuticals Corporation a clinicalstage company developing a new class of RNAibased therapeutics outlined its 2018 business strategy during a webcast presentation at the Biotech Showcase conference which brought .. Read More...

Suppliers of the Month

Product Launch



Latest Reports


Latest Projects


Expert Talk

Bayer Pharmaceuticals

Bayer Pharmaceuticals Christoph Huwe PhD CAAM is a Strategic Alliance Manager Therapeutics at Bayer AG Pharmaceuticals with a focus on the BayerEvotec Endometriosis BayerEvotec Kidney Diseases BayerOncoMed Oncology strategic alliances and the Tuberculosis Drug Accelerator consortium He is also a member of Bayers Alliance. Read More...
Christoph Huwe
Strategic Alliance Manager Therapeutics